AstraZeneca Q1 2026 results published on April 29, 2026, reveal a company in high gear, delivering a robust 8% increase in total revenue to $15,288 million. This financial performance, characterized by consistent commercial execution and significant R&D milestones, underscores the pharmaceutical giant’s trajectory toward its ambitious 2030 targets.
Financial Performance Highlights in AstraZeneca Q1 2026 Results
AstraZeneca’s core operating profit rose by 12% during the first quarter, reflecting the company’s ability to scale its operations while maintaining a healthy core gross margin of 83%. Despite a slight revenue miss compared to some analyst expectations, the AstraZeneca Q1 2026 results show a core earnings per share (EPS) of $2.58, a 5% increase at constant exchange rates (CER).
The growth was primarily fueled by the Oncology and Rare Disease sectors. Oncology alone contributed $6.8 billion, a 16% increase, while Rare Disease revenues reached $2.42 billion.
Key Financial Indicators (Q1 2026)
| Metric | Q1 2026 Value | Growth (CER) |
| Total Revenue | $15,288 million | +8% |
| Product Sales | $14,386 million | +7% |
| Core Operating Profit | $5,352 million | +12% |
| Core EPS | $2.58 | +5% |
| Core Gross Margin | 83% | +1pp |
Learn More: Novartis Q1 2026 Results: Strong Growth in Priority Brands Amid Generic Erosion
Clinical Pipeline Successes and Regulatory Approvals
A standout feature of the AstraZeneca Q1 2026 results is the “catalyst-rich” pipeline progress. CEO Pascal Soriot highlighted positive Phase III readouts for four high-value programs, including two new molecular entities (NMEs): tozorakimab and efzimfotase alfa.
Tozorakimab, a potential first-in-class IL-33 biologic, met primary endpoints in the OBERON, TITANIA, and MIRANDA trials for COPD, demonstrating significant reductions in exacerbations. Meanwhile, efzimfotase alfa showed promising results in the MULBERRY and CHESTNUT trials for hypophosphatasia (HPP), a rare genetic bone disease.
Clinical Trial Readouts and Pipeline Milestones
| Medicine | Trial / Indication | Status / Outcome |
| Tozorakimab | OBERON, TITANIA, MIRANDA (COPD) | Met Primary Endpoints: Significant reduction in exacerbations. |
| Efzimfotase Alfa | MULBERRY (Pediatric HPP) | Met Primary Endpoint: Improved skeletal health at 25 weeks. |
| Efzimfotase Alfa | CHESTNUT (HPP Switch Study) | Success: Maintained efficacy/safety after switching from Strensiq. |
| Imfinzi | EMERALD-3 (Locoregional HCC) | Met Primary Endpoint. |
| Truqap | Various Indications | Growth: +47% revenue increase following recent launches. |
Novo Nordisk Ziltivekimab ZEUS Trial: Phase 3 Cardiovascular Readout Misses Primary MACE Reduction Target
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated […]
Roche Biocon Perjeta Lawsuit: Genentech Sues Over Biocon’s Breast-Cancer Biosimilar in New Jersey Court
Genentech and Roche have filed a new patent-infringement lawsuit against Biocon in New Jersey federal court, alleging Biocon's proposed pertuzumab biosimilar infringes patents covering Perjeta, […]
Sanofi Q2 2026 Results: Dupixent Sales Growth Powers Record Second Quarter as Guidance is Upgraded
Sanofi posted 17.8% Q2 2026 sales growth at constant exchange rates, driven by Dupixent's record €5.2 billion quarter and a 48.3% jump in pharma launches, […]
Strategic Expansion and 2026 Guidance
Beyond the financial data, the AstraZeneca Q1 2026 results presentation detailed new strategic collaborations. In April 2026, AstraZeneca closed a $1.2 billion upfront agreement with CSPC Pharmaceuticals to advance next-generation therapies for obesity and type 2 diabetes.
